Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01888198 · ClinicalTrials.gov registry record
Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
A clinical trial of Renal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 294
- Enrollment target
- 6
- Study locations
NCT01888198 is a study of Renal Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 294 participants, below the 600-participant average among 29 other Renal Cancer trials with a reported enrollment target (51% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT01888198, a study of Renal Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 294 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or prospective data collection
Conditions Studied
Interventions
- BEHAVIORAL (EORTC QLQ-C30) questionnaire
- BEHAVIORAL EuroQol EQ-5D 7-item questionnaire
Study Locations (6)
California
- University of California, Los Angeles - Los Angeles
Maryland
- University of Maryland Medical Center - Baltimore
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Rhode Island
- Rhode Island Hospital - Providence
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2013-06 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01888198
The ClinicalTrials.gov registry entry for NCT01888198 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 29 other Renal Cancer trials with a reported enrollment target (51% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cancer appearing as the primary indexed condition, and to 2 interventions - of which (EORTC QLQ-C30) questionnaire is the first listed.
NCT01888198 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT01888198 about?
NCT01888198 is a clinical study titled "Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment". The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or...
What is the current status of trial NCT01888198?
This trial is currently active not recruiting. The enrollment target is 294 participants. The study started on 2013-06. Estimated completion is 2026-06.
What conditions does trial NCT01888198 study?
This clinical trial studies the following conditions: Renal Cancer.
What interventions are being tested in trial NCT01888198?
The interventions under investigation include: (EORTC QLQ-C30) questionnaire (BEHAVIORAL), EuroQol EQ-5D 7-item questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT01888198?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01888198 being conducted?
This trial has 6 study locations across California, Maryland, New York, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Kidney Cancer DNA Registry
RECRUITING
-
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
RECRUITING
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
RECRUITING · Phase 1
-
Advanced Diffusion Imaging in Renal Cancer Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.